Katharina Valentin, Thomas Georgi, Regina Riedl, Haleh Aminfar, Christoph Singer, Thomas Klopstock, Andreas Wedrich, Mona Schneider
The aim of this study was to evaluate the therapeutic effect of idebenone in patients with OPA1-dominant optic atrophy (DOA). Sixteen patients with genetically confirmed OPA1-DOA were treated with 900 mg idebenone daily for 12 months. The primary endpoint was the best recovery/least deterioration of visual acuity. Secondary endpoints were the changes of visual acuity, colour vision, contrast sensitivity, visual field, peripapillary retinal nerve fibre layer thickness (pRNFLT), and visual-related quality of life...
2023: Neuro-ophthalmology